| Stage | CPRX | % of rev | LLY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $149M | 100.00% | $24.4B | 100.00% | LLY ×163.31 |
| Gross profit | $135M | 90.31% | $20.5B | 83.88% | CPRX +6.4pp |
| Operating income | $73M | 49.02% | $8.6B | 35.28% | CPRX +13.7pp |
| Pre-tax income | $84M | 56.38% | $8.4B | 34.46% | CPRX +21.9pp |
| Net income | $64M | 42.66% | $6.5B | 26.44% | CPRX +16.2pp |
| Stage | CPRX | LLY | Gap · A − B |
|---|---|---|---|
| Revenue | $149M100.00% | $24.4B100.00% | LLY ×163.31 |
| Gross profit | 90.31%$135M | 83.88%$20.5B | CPRX +6.4pp |
| Operating income | 49.02%$73M | 35.28%$8.6B | CPRX +13.7pp |
| Pre-tax income | 56.38%$84M | 34.46%$8.4B | CPRX +21.9pp |
| Net income |
| 42.66%$64M |
| 26.44%$6.5B |
| CPRX +16.2pp |
None
No disclosed counterparties: CPRX.